AVNSAvanos Medical, Inc.
Is the price fair?
A demanding price: priced for +34% a year vs +2% a year delivered and at the top of its own P/E range.
Priced for ~34% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 70.7 vs a 37.3 median over 18 quarters (+90% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AVNS's price assumes
Today's price asks for 34% free cash flow growth a year; over the last three years Avanos Medical, Inc. delivered −51%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.64%
Free cash flow yield · Medical Devices median 4.2%
- Growth the price implies
- +34%
Growth the price implies · The price pays for +34% free cash flow growth a year for a decade; the business has delivered −51% a year over the last three.
- Price / book
- 0.85
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 0.85
- EV / EBIToperating margin −8.8%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 0.96
- Free cash flow, trailing twelve months
- $7.5M
- Market capitalisation46.8 million shares, counted Apr 28, 2026
- $1.17B
- 3-year revenue growth
- +1.5%
- 3-year free cash flow growth
- −51%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Medical Devices
The closest names by size in the same industry